TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17925518

Group type: EXPERIMENTAL
Intervention: Behavioral skills maintenance (BSM)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Social facilitation maintenance (SFM)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: BSM and SFM together
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: SFM alone
Number of subjects: 204
Study: 15266759

Group type: EXPERIMENTAL
Intervention: Vaginal sildenafil (25 mg four times daily intravaginally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaginal estradiol (E2)
Number of subjects: 0
Study: 11866680

Group type: EXPERIMENTAL
Intervention: Isotretinoin (13‐cis‐retinoic acid)
Number of subjects: 0
Study: 9880129

Group type: EXPERIMENTAL
Intervention: Wrist cuff oscillometric blood pressure device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mercury manometer
Number of subjects: 100
Study: 7728133

Group type: EXPERIMENTAL
Intervention: FTBI/VP-16 regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FTBI/VP-16 regimen with added CY 60 mg/kg
Number of subjects: 0
Study: 2706191

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal
Number of subjects: 7
Study: 29040021

Group type: EXPERIMENTAL
Intervention: Flexible Sigmoidoscopy (FS)
Number of subjects: 1984

Group type: EXPERIMENTAL
Intervention: CT Colonography (CTC)
Number of subjects: 1984

Group type: COMPARATOR
Intervention: CT Colonography (CTC) Nonattendees
Number of subjects: 1984
Study: 28257942

Group type: EXPERIMENTAL
Intervention: Optimal defaults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suboptimal defaults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent empowerment priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral priming
Number of subjects: 0
Study: 26650152

Group type: COMPARATOR
Intervention: Standard-care group (permethrin to affected persons and contacts)
Number of subjects: 2051

Group type: EXPERIMENTAL
Intervention: Permethrin group (mass administration of permethrin)
Number of subjects: 2051

Group type: EXPERIMENTAL
Intervention: Ivermectin group (mass administration of ivermectin)
Number of subjects: 2051
Study: 23499145

Group type: EXPERIMENTAL
Intervention: Anterior thoracic manipulation of T1-4
Number of subjects: 36

Group type: COMPARATOR
Intervention: Activator-based placebo manipulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: No T-spine contact control
Number of subjects: 36
Study: 22468309

Group type: EXPERIMENTAL
Intervention: HanFangJiaSu
Number of subjects: 71

Group type: COMPARATOR
Intervention: XiFeiNing
Number of subjects: 71
Study: 19938938

Group type: EXPERIMENTAL
Intervention: Cessation intervention for smokeless tobacco users
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Cessation intervention for smokers
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control condition for smokeless tobacco users
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control condition for smokers
Number of subjects: 337
Study: 16753403

Group type: EXPERIMENTAL
Intervention: PlasmaKinetic prostate vaporization
Number of subjects: 160

Group type: COMPARATOR
Intervention: Transurethral prostate resection
Number of subjects: 160
Study: 15003080

Group type: EXPERIMENTAL
Intervention: Paroxetine + Clonazepam (1.0 to 2.0 mg/day, divided b.i.d.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Paroxetine + Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Paroxetine + Clonazepam
Number of subjects: 28
Study: 11762415

Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan) at a dose of 0.4 mCi/kg for patients with platelet counts > 150,000 and < 25% bone marrow involvement; 0.3 mCi/kg for patients with platelet counts between 100,000-149,000.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab at a standard dose of 375 mg/m2 weekly for four weeks (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonrandomized trial of Zevalin in patients refractory to rituximab.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase II study of reduced dose of Zevalin in patients with mild thrombocytopenia.
Number of subjects: 0
Study: 9327113

Group type: EXPERIMENTAL
Intervention: Marezine (50 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dramamine (50 mg)
Number of subjects: 23
Study: 7878561

Group type: EXPERIMENTAL
Intervention: Occlusion at total lung capacity (TLC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Occlusion at residual volume (RV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Occlusion at RV
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Occlusion at TLC
Number of subjects: 12
Study: 2564563

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Ketoconazole 200 mg daily
Number of subjects: 37
Study: 5440241

Group type: EXPERIMENTAL
Intervention: Routine multiple blood tests
Number of subjects: 296
Study: 31690281

Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention using a web-based tool, duration: 12 months
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Multimodal lifestyle intervention using a web-based tool
Number of subjects: 244

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 244
Study: 28500463

Group type: EXPERIMENTAL
Intervention: NIO™
Number of subjects: 87

Group type: COMPARATOR
Intervention: BIG®
Number of subjects: 87

Group type: COMPARATOR
Intervention: EZ‐IO®
Number of subjects: 87

Group type: COMPARATOR
Intervention: Jamshidi
Number of subjects: 87
Study: 25409592

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (160 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 17
Study: 23306100

Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 385

Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 385
Study: 16788389

Group type: EXPERIMENTAL
Intervention: Nursing intervention program along with usual rehabilitation care
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual rehabilitation care alone
Number of subjects: 155
Study: 12590012

Group type: EXPERIMENTAL
Intervention: Low-dose hormonal replacement therapy (LD‐HRT), 17beta‐estradiol (1 mg/day) and norethisterone acetate (0.5 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium supplement (controls)
Number of subjects: 50
Study: 10383370

Group type: EXPERIMENTAL
Intervention: 6.0-mm external bore nasogastric tube
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2.85-mm external bore nasogastric tube
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 17
Study: 7631298

Group type: COMPARATOR
Intervention: Randomised treatment
Number of subjects: 0
Study: 1849536

Group type: EXPERIMENTAL
Intervention: High sodium intake
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 100

Group type: COMPARATOR
Intervention: Crossover protocol of sodium intake
Number of subjects: 100
Study: 6756936

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 20 mg
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 30 mg
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg plus codeine 40 mg
Number of subjects: 266

Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 266
Study: 29700813

Group type: EXPERIMENTAL
Intervention: QbTest report provided immediately (QbOpen group)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Assessment as usual without QbTest report (QbBlind group)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Health economic analysis
Number of subjects: 267
Study: 28736511

Group type: EXPERIMENTAL
Intervention: MSM (OptiMSM®) at 3 g/day for 21 days prior to the race and for two days after (23 total)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: MSM (OptiMSM®)
Number of subjects: 22
Study: 25319739

Group type: EXPERIMENTAL
Intervention: FIB-4 index
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: FIB-4 index (overestimated score)
Number of subjects: 631
Study: 23295321

Group type: EXPERIMENTAL
Intervention: Instructor feedback
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no instructor feedback)
Number of subjects: 99
Study: 21942465

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg twice a day
Number of subjects: 158

Group type: COMPARATOR
Intervention: Diclofenac 75 mg thrice a day
Number of subjects: 158
Study: 18837809

Group type: EXPERIMENTAL
Intervention: Home videoconferencing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone calls
Number of subjects: 0
Study: 15668218

Group type: EXPERIMENTAL
Intervention: Behavioural modification group (BM)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Fundamental motor skills group (FMS)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Combined BM and FMS group
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control (usual classroom lessons)
Number of subjects: 293
Study: 12829141

Group type: EXPERIMENTAL
Intervention: Postoperative RT combined with mitomycin C (15 mg/m2 after 10 Gy) and bleomycin (5 mg twice a week during RT to a total of 70 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Postoperative RT alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Postoperative RT combined with mitomycin C and bleomycin
Number of subjects: 114
Study: 10817348

Group type: EXPERIMENTAL
Intervention: Epirubicin (120 mg/m2, i.v. bolus every 3 weeks)
Number of subjects: 127
Study: 8664976

Group type: EXPERIMENTAL
Intervention: IGF-I (10 micrograms.kg‐1.h‐1 sc for 5 days) in healthy subjects
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IGF-I (10 micrograms.kg‐1.h‐1 sc for 7 days) in subjects with GH and TSH deficiency
Number of subjects: 16

Group type: COMPARATOR
Intervention: Growth hormone (GH) alone (2 IU m‐2 sc q.i.d.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: GH plus IGF-I
Number of subjects: 16
Study: 2052337

Group type: EXPERIMENTAL
Intervention: Cefadroxil, 1 gm/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Cephalexin, 250 mg four times a day
Number of subjects: 116
Study: 6619055

Group type: COMPARATOR
Intervention: Piperacillin (300 mg/kg/day) alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Piperacillin (300 mg/kg/day) and tobramycin (7 mg/kg/day) iv
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Piperacillin and tobramycin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 14
Study: 31545507

Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg once daily
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg once daily
Number of subjects: 230
Study: 30577903

Group type: EXPERIMENTAL
Intervention: Parent/Youth intervention
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Parent Only intervention
Number of subjects: 532

Group type: COMPARATOR
Intervention: Comparison group (Treatment as usual)
Number of subjects: 532
Study: 28408635

Group type: EXPERIMENTAL
Intervention: Restriction group (RES, n=8) - subjects slept two-thirds of normal sleep time for 8 days and 8 nights
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CON, n=9) - subjects allowed to sleep their usual sleep time
Number of subjects: 17

Group type: COMPARATOR
Intervention: Both groups (RES and CON) during REM sleep
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: After 8 days of moderate sleep deprivation
Number of subjects: 17
Study: 26975625

Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 25131129

Group type: EXPERIMENTAL
Intervention: Cyclosporine A‐based immunosuppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus‐based immunosuppression
Number of subjects: 0
Study: 22492517

Group type: COMPARATOR
Intervention: NIHSS at 1 to 3 hours
Number of subjects: 312

Group type: COMPARATOR
Intervention: NIHSS at 24 hours
Number of subjects: 312

Group type: COMPARATOR
Intervention: NIHSS at 90 days
Number of subjects: 312

Group type: COMPARATOR
Intervention: Spontaneous improvement from 1-3 hours to 24 hours
Number of subjects: 312

Group type: COMPARATOR
Intervention: NIHSS scores associated with final modified Rankin Scale of 2
Number of subjects: 312

Group type: COMPARATOR
Intervention: Correlation between NIHSS and final modified Rankin Scale
Number of subjects: 312
Study: 20175431

Group type: EXPERIMENTAL
Intervention: EGCG 270 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo 270 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EGCG 270 mg + Caffeine 3 mg/kg
Number of subjects: 8
Study: 17471993

Group type: EXPERIMENTAL
Intervention: Ozone therapy (OT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no ozone pretreatment)
Number of subjects: 20
Study: 15955104

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal skin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-lesional psoriatic skin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lesional psoriatic skin
Number of subjects: 0
Study: 12095466

Group type: EXPERIMENTAL
Intervention: Diagnostic nerve blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional, anesthetic, and ablative techniques
Number of subjects: 0
Study: 9883103

Group type: EXPERIMENTAL
Intervention: Familiarity rating
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Emotionality rating
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Motor Activity rating
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Memorability rating
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control studies on Familiarity dimension
Number of subjects: 128
Study: 7611390

Group type: EXPERIMENTAL
Intervention: Higher protein diet (1.62 +/- 0.02 g protein.kg-1.day-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lower protein diet (0.80 +/- 0.02 g protein.kg-1.day-1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both diets during resistance training
Number of subjects: 12
Study: 2223335

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.01 mg kg‐1 administered 5 min after midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 2 mg and 5 mg i.v.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flumazenil alone
Number of subjects: 0
Study: 28988

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Theophylline-Ephedrine combination
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ephedrine-Butabarbital combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Butabarbital
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Guaifenesin
Number of subjects: 20
Study: 31690298

Group type: EXPERIMENTAL
Intervention: Immunization education program (individual education sessions involving fathers)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Immunization education program
Number of subjects: 225
Study: 28545998

Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg
Number of subjects: 94

Group type: COMPARATOR
Intervention: Aflibercept 1 mg/kg
Number of subjects: 94
Study: 26506062

Group type: EXPERIMENTAL
Intervention: Plyometric training group (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Warm-up (n = 32)
Number of subjects: 32
Study: 23746392

Group type: EXPERIMENTAL
Intervention: Long backboard (LBB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vacuum mattress splint (VMS)
Number of subjects: 60
Study: 21465518

Group type: EXPERIMENTAL
Intervention: Induction treatment with assessment of bone marrow cytology on day 6
Number of subjects: 164
Study: 19781835

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study: 16709019

Group type: EXPERIMENTAL
Intervention: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via convection-enhanced delivery (CED)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intratumoral injection of the human‐murine chimeric mAb Ch81C6 labeled with the 123I tracer via bolus injection
Number of subjects: 0
Study: 15305197

Group type: EXPERIMENTAL
Intervention: Cancer genetic counselling at five UK centres
Number of subjects: 256
Study: 11781670

Group type: COMPARATOR
Intervention: Standard enteral formula (group I)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Enterotropic peptide-based formula enriched with n-3 fatty acids (group II)
Number of subjects: 74
Study: 9323063

Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (n=39)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 77
Study: 8228934

Group type: EXPERIMENTAL
Intervention: Four-dose vaccination scheme starting at month 3 (months 3, 4, 5, and 11)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Three-dose vaccination scheme starting at birth (months 0, 1, and 6)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Four-dose vaccination scheme starting at birth (months 0, 1, 2, and 11)
Number of subjects: 162
Study: 2878016

Group type: EXPERIMENTAL
Intervention: Combined H1 (diphenhydramine hydrochloride) and H2 (cimetidine) histamine antagonists
Number of subjects: 10

Group type: COMPARATOR
Intervention: H1 antagonist (diphenhydramine hydrochloride) alone
Number of subjects: 10
Study: 28655271

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises
Number of subjects: 143

Group type: COMPARATOR
Intervention: Sham rESWT and supervised exercises
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy (rESWT) and supervised exercises (subgroup analysis)
Number of subjects: 143
Study: 26682914

Group type: EXPERIMENTAL
Intervention: Simple-step maneuver (SSM)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Multi-step maneuver (MSM)
Number of subjects: 344
Study: 25487932

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection (15 IU to 45 IU, average 31.2±13.9 IU) plus conventional physical therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional physical therapy (PY)
Number of subjects: 37
Study: 22385946

Group type: EXPERIMENTAL
Intervention: Depressed group (GDS ≥10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondepressed group (GDS <10)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression (as a predictor)
Number of subjects: 0
Study: 20618883

Group type: EXPERIMENTAL
Intervention: 4 g cholestyramine powder
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 12 g cholestyramine powder
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control drink powder
Number of subjects: 42
Study: 18689377

Group type: EXPERIMENTAL
Intervention: 24-h recall
Number of subjects: 157

Group type: COMPARATOR
Intervention: 3-d weighed food records
Number of subjects: 157
Study: 15747157

Group type: EXPERIMENTAL
Intervention: DCM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CAD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of DCM and CAD
Number of subjects: 20
Study: 12051571

Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexloxiglumide 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated dosing of Dexloxiglumide 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated dosing of Dexloxiglumide 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated dosing of Dexloxiglumide 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dexloxiglumide (all doses)
Number of subjects: 12
Study: 10420110

Group type: EXPERIMENTAL
Intervention: Type I diabetes
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Type II diabetes
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 75
Study: 8789518

Group type: EXPERIMENTAL
Intervention: Children who were told about the contents of a deceptive box (intervention group)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Children who saw inside the box (control group)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Narrative procedure (intervention)
Number of subjects: 121
Study: 2248124

Group type: EXPERIMENTAL
Intervention: Successfully restrained drinkers (light drinkers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unsuccessfully restrained drinkers (heavy drinkers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrestrained drinkers
Number of subjects: 0
Study: 7192147

Group type: EXPERIMENTAL
Intervention: Psychoergic drugs (3 stimulants)
Number of subjects: 40
Study: 6405838

Group type: EXPERIMENTAL
Intervention: Postoperative total parenteral nutrition (TPN)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TPN-5-FU combination
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-TPN-5-FU
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TPN-5-FU
Number of subjects: 57
Study: 31921171

Group type: EXPERIMENTAL
Intervention: Tacrolimus TTR > 78%
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Tacrolimus TTR < 78%
Number of subjects: 1241

Group type: EXPERIMENTAL
Intervention: Tacrolimus TTR
Number of subjects: 1241
Study: 29032574

Group type: EXPERIMENTAL
Intervention: Submerged healing protocol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transmucosal healing protocol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40